Stock jumped 31.20% on announcement of significant collaboration deal with Alnylam worth up to $1.13 billion in potential payments. The partnership validates Tenaya's target identification and validation capabilities for cardiovascular disease treatments.
Articles that tag TNYA but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
